ETC-1002
ETC-1002-003
Phase 2 small_molecule completed
Quick answer
ETC-1002 for Dyslipidemia is a Phase 2 program (small_molecule) at Esperion Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Esperion Therapeutics
- Indication
- Dyslipidemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed